Lifitegrast
Active ingredient: Lifitegrast
In short: Lifitegrast ophthalmic solution 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
What is Lifitegrast used for?
Lifitegrast ophthalmic solution 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Lifitegrast dosage
Instill one drop of lifitegrast ophthalmic solution twice daily (approximately 12 hours apart) into each eye using a single-dose container. Discard the single-dose container immediately after using in each eye.
Contact lenses should be removed prior to the administration of lifitegrast ophthalmic solution and may be reinserted 15 minutes following administration.
How to take Lifitegrast — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Handling
the Single-Dose Container
Advise patients not to touch the tip of the single-dose container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
Use
with Contact Lenses
Advise patients that contact lenses should be removed prior to administration of lifitegrast ophthalmic solution and can be reinserted 15 minutes after administration .
Administration
Advise patients that the solution from one single-dose container is to be used immediately after opening. It can be used to dose both eyes. The single-dose container, including any remaining contents should be discarded immediately after administration .
Storage Information
Instruct patients to store single-dose containers in the original foil pouch until ready to use .
Dispense with Patient Information and Instructions for Use available at:
https://www.aurobindousa.com/medication-guides/
Distributed by:
Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road East Windsor, NJ 08520
Manufactured by:
Eugia Pharma Specialities Limited
Hyderabad - 500032 India
Warnings & precautions
Do not take this medicine if: Lifitegrast is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation .
Lifitegrast side effects
The following serious adverse reactions are described elsewhere in the labeling:
• Hypersensitivity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In five clinical trials of DED conducted with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received lifitegrast 5%). The majority of patients (84%) had less than or equal to 3 months of treatment exposure. One hundred-seventy patients were exposed to lifitegrast for approximately 12 months. The majority of the treated patients were female (77%). The most common adverse reactions reported in 5% to 25% of patients were instillation-site irritation, dysgeusia, and reduced visual acuity.
Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, and sinusitis.
The following adverse reactions have been identified during post-approval use of lifitegrast. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. …
About this medicine
The chemical name for lifitegrast is (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid. The molecular formula of lifitegrast is C29H24Cl2N2O7S and its molecular weight is 615.5 g/mol. The structural formula of lifitegrast is:
*Chiral center
Lifitegrast is a white to off-white powder, which is practically insoluble in water.
Lifitegrast ophthalmic solution 5% is a lymphocyte function-associated antigen-1 (LFAÂ-1) antagonist supplied as a sterile, clear, colorless to slightly brownish-yellow colored, isotonic solution of lifitegrast with a pH of 7.0 to 8.0 and an osmolality range of 200 to 330 mOsmol/kg.
Lifitegrast ophthalmic solution contains Active: lifitegrast 50 mg/mL; Inactives: sodium chloride, dibasic sodium phosphate anhydrous, sodium thiosulfate pentahydrate, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1d4b4b61-79da-4b6f-bb19-056d111bf400. Read the full official label on DailyMed.
Related medicines
Azithromycin Latanoprost Amoxicillin and Clavulanate Cephalexin Sulfamethoxazole and Trimethoprim Ofloxacin Timolol Cefdinir